ElectroCore, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual Form 10-K, not a standalone fourth-quarter filing. The company is a commercial-stage bioelectronic medicine and wellness company focused on non-invasive vagus nerve stimulation (nVNS) products, including prescription gammaCore and wellness or human-performance products Truvaga and TAC-STIM.
Business Context
- gammaCore is FDA-cleared for several migraine, cluster headache, paroxysmal hemicrania and hemicrania continua indications. Truvaga and TAC-STIM are marketed as non-prescription general-wellness products.
- Revenue is concentrated in government and government-funded channels: VA/Department of Defense represented 60.8% of 2022 revenue, while the United Kingdom National Health Service represented 15.1%.
- The VA Federal Supply Schedule contract, a key U.S. sales channel, is scheduled to expire January 15, 2024. Management intends to seek an extension, but renewal and terms are uncertain.
- The company launched Truvaga and TAC-STIM during 2022 and continued expanding cash-pay, direct-to-physician, direct-to-consumer and ecommerce channels.
Financial Performance and Liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Net sales | $8.592 million | $5.451 million | +$3.141 million; +58% |
| Gross profit | $6.976 million | $4.066 million | +$2.910 million |
| Gross margin | 81% | 75% | +6 percentage points |
| Research and development | $5.520 million | $2.536 million | +$2.984 million |
| SG&A | $24.330 million | $21.573 million | +$2.757 million |
| Loss from operations | $(22.874) million | $(20.043) million | Loss increased $2.831 million |
| Net loss | $(22.162) million | $(17.218) million | Loss increased $4.944 million |
| Basic and diluted loss per share | $(4.69) | $(4.36) | Higher loss per share |
| Cash used in operating activities | $(16.645) million | $(13.627) million | Use increased $3.018 million |
- Revenue growth reflected higher sales across VA, U.S. commercial and international channels, plus $139,000 of Japanese licensing revenue from the Teijin agreement. International revenue was affected by a stronger U.S. dollar.
- Gross-margin expansion was attributed primarily to device-licensing arrangements, greater sales of longer-duration therapy and refill kits, and licensing revenue without associated cost of goods sold.
- Cash, cash equivalents and restricted cash totaled $17.962 million at year-end, compared with $34.689 million at year-end 2021. Cash and cash equivalents alone were $17.712 million, plus $250,000 of restricted cash.
- Total assets were $24.756 million and total liabilities were $7.670 million at December 31, 2022. The company reported an accumulated deficit of $146.370 million.
- Year-end inventory was $4.176 million, including $2.194 million classified as noncurrent; inventory reserves for obsolescence totaled $668,000.
- The company had no cash provided by investing or financing activities in 2022. Year-end financing obligations included approximately $264,000 under an insurance-premium financing arrangement and $699,000 of operating lease liabilities; the filing does not identify material conventional long-term debt.
Material Changes Versus 2021
- Sales increased substantially, but operating expenses grew faster than gross profit, resulting in a larger operating and net loss.
- Research and development expense more than doubled as the company invested in next-generation, smartphone-integrated and smartphone-connected therapy delivery technology.
- SG&A increased as the company invested in sales and marketing for cash-pay, ecommerce and expanded commercial channels.
- 2021 included unusual benefits that did not recur in 2022: a $1.422 million gain from forgiveness of a Paycheck Protection Program loan and a $549,000 gain from termination of the Australian joint venture.
- 2022 revenue mix shifted toward VA/DoD, which increased from 59.8% to 60.8% of revenue, while NHS revenue declined from 24.1% to 15.1%.
- Operating cash burn increased and available liquidity declined by approximately $16.7 million during the year.
Outlook, Risks and Unusual Items
- Management expects continued substantial operating losses and negative operating cash flow in 2023 while investing in sales, marketing and the next-generation platform.
- The auditor included an explanatory paragraph stating that substantial doubt exists about the company’s ability to continue as a going concern within one year of issuance of the financial statements. Management may need additional financing or may have to reduce or curtail activities.
- The company has an effective $75 million shelf registration statement, but future equity or debt financing may be unavailable on acceptable terms and could dilute existing stockholders or create senior claims.
- Key commercial dependencies include renewal of the VA FSS contract, continued NHS funding and favorable NICE guidance or pricing, third-party reimbursement, adoption of direct-to-consumer initiatives, and consumer acceptance of Truvaga and TAC-STIM.
- Pending securities class actions and related derivative lawsuits remain unresolved. The company has not accrued a loss because it cannot estimate the probability or range of potential loss; defense costs, settlements or judgments could materially affect liquidity.
- Supply-chain exposure includes third-party and potentially single-source suppliers, including suppliers in China. The filing also cites inflation, foreign-exchange movements, COVID-19 effects, regulatory changes, reimbursement uncertainty, competition and cybersecurity risks.
- The company completed a 1-for-15 reverse stock split effective February 15, 2023 and subsequently regained Nasdaq minimum bid-price compliance. The Series A preferred stock created for the reverse-split vote was redeemed and eliminated in March 2023.
- The filing states that the company’s internal control over financial reporting and disclosure controls were effective as of December 31, 2022; the auditor was not required to provide an internal-control attestation because the company remained an emerging growth company.
Investor Verification Checklist
- Verify the company’s current liquidity, monthly cash burn and financing plans after the December 31, 2022 balance-sheet date.
- Track renewal or replacement of the VA FSS contract before its January 15, 2024 expiration.
- Assess whether VA/DoD and NHS concentration has declined and whether cash-pay, ecommerce, Truvaga and TAC-STIM channels are generating meaningful recurring revenue.
- Review gross-margin sustainability, including the useful lives and recoverability of licensed devices and the risk of additional inventory-obsolescence charges.
- Monitor the NHS/NICE review and any changes to the U.K. MedTech Funding Mandate program.
- Review the status, insurance coverage and potential exposure from the securities class actions and derivative litigation.
- Confirm the impact of the reverse stock split, outstanding equity awards and any future capital raises on share count and dilution.